The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to ...
The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...
In a bid to improve competition in the industry, the U.S. Federal Trade Commission is challenging the patents of 20 different ...
The U.S. Federal Trade Commission (FTC) is not done with its crackdown on what it views as improper listing of patents with the FDA. After an initial round of challenges launched in November ...
The FTC sent warning letters to 10 pharmaceutical companies—including Novo Nordisk, AstraZeneca, GlaxoSmithKline and ...
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, ...
The move targets over 300 listings for 20 branded products from companies such as AstraZeneca, Novo Nordisk, and GSK that the ...
Boehringer Ingelheim, one of 10 companies sent a warning letter by the FTC disputing the accuracy of patent listings in the ...